Type of Mesothelioma:
Radiologist’s Guide to the Ninth Edition TNM Staging System for Quantitative and Qualitative Assessment of Pleural Mesothelioma
Radiology 2025 September [Link] David J Murphy, Anna K Nowak, Thomas Frauenfelder, Michelle S Ginsberg, Hiroshi Kodama, Veronica Lenge de Rosen, Maria Mayoral, Christopher Straus, Giulia Benedetti, Valerie W Rusch, Ritu R Gill Abstract Pleural mesothelioma is a highly lethal, rare thoracic malignant neoplasm arising from mesothelial cells. Previous versions of the clinical TNM staging…
Read MoreInclusion of anti-vascular therapy as a promising option for later-line treatment of malignant pleural mesothelioma: a retrospective study
Journal of Thoracic Disease 2025 August 31 [Link] Keda Shao, Di Wu, Qian Wang, Dong Wang, Yue Hao, Bihui Li, Jianhui Huang, Ziyan Yang, Jingxun Wu, Long Huang, Wenfeng Li, Rui Meng, Jian Feng, Jianfei Fu, Huijing Feng, Shengjie Yang, Ling Xu, Xuefei Shi, Miao Li, Yujuan Wang, Chunwei Xu, Zhengbo Song Abstract Background: Malignant…
Read MoreMalignant Local Seeding in Procedure Tracts of Pleural Mesothelioma: Incidence and Novel Risk Factors in 308 Patients
Cancers 2025 August 26 [Link] Moshe Lapidot, Emanuele Mazzola, Raphael Bueno Abstract Background/Objectives: Unlike other thoracic malignancies, seeding malignant cells along surgical tracts is a known complication of invasive diagnostic or therapeutic procedures for pleural mesothelioma (PM). We report the tract dissemination rate and risk factors in 308 consecutive patients treated over 9 years in…
Read MoreCombining Chemotherapeutic Agents, Targeted Therapies, Vaccines and Natural Bioactive Compounds for Mesothelioma: Advances and Perspectives
Oncology Research 2025 August 28 [Link] Raffaele Carrano, Carlotta Zucca, Nicla Cristina, Martina Grande, Eleonora Leti Maggio, Riccardo Bei, Antonio Infante, Chiara Focaccetti, Valeria Lucarini, Loredana Cifaldi, Laura Masuelli, Luciano Mutti, Camilla Palumbo, Monica Benvenuto, Roberto Bei Abstract Mesothelioma is a rare and aggressive cancer with a poor prognosis and limited therapeutic options. Despite recent…
Read MorePerioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses
Nature Medicine 2025 September 8 [Link] Joshua E Reuss, Paul K Lee, Reza J Mehran, Chen Hu, Suqi Ke, Amna Jamali, Mimi Najjar, Noushin Niknafs, Jaime Wehr, Ezgi Oner, Qiong Meng, Gavin Pereira, Samira Hosseini-Nami, Mark Sausen, Marianna Zahurak, Richard J Battafarano, Russell K Hales, Joseph Friedberg, Boris Sepesi, Julie S Deutsch, Tricia Cottrell, Janis…
Read MorePleural Mesothelioma: Pathogenesis, Diagnosis, Treatment, Prognosis, and Survival
MedComm 2025 September 1 [Link] Libo Zhang, Meijuan Huang Abstract Pleural mesothelioma (PM) presents significant challenges in clinical management, with current treatment options such as chemotherapy, anti-angiogenic therapies, and immunotherapies only modestly extending progression-free survival (PFS) and overall survival (OS). Another relevant reason is the absence of subsequent-line therapy strategies following progression of PM after…
Read MoreCo-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
Molecular Cancer Therapeutics 2025 September 5 [Link] Yuan Xu, Cristian G Medina, Deborah R Surman, Lacey E Dobrolecki, Monica Vilchis, Maheshwari Ramineni, Susan G Hilsenbeck, Yanming Li, Naren Li, Siqi Wu, Jaylon C Aggison, Xi Chen, Yi Zhu, Ying H Shen, R Taylor Ripley Abstract Diffuse mesothelioma is a rare but highly aggressive and treatment-resistant…
Read MoreInhibition of YB-1 phosphorylation enhances cisplatin activity and disrupts cell division in pleural mesothelioma
British Journal of Cancer 2025 September 4 [Link] Karin Schelch, Nadine Maach, Muhammad Hashim, Benjamin Zitta, Dominik Kirchhofer, Gerald Timelthaler, Anna Solta, Dominik Emminger, Verena Kopatz, Mir A Hoda, Walter Berger, Clemens Aigner, Balazs Dome, Glen Reid, Michael Grusch Abstract Background: The cold-shock domain protein YB-1 is overexpressed in pleural mesothelioma (PM) and was shown…
Read MoreEvaluation of SOX6 immunohistochemical expression as a diagnostic marker in the distinction of epithelioid mesothelioma from lung carcinomas
Annals of Diagnostic Pathology 2025 August 26 [Link] Fatma Samy Hafez, Safaa Mahmoud Mohamed Abdelkhalek, Shaimaa Abdelraouf Elgohary Abstract Epithelioid mesothelioma (EM) is a pleural malignancy whose many histopathologic patterns may overlap considerably with those of lung adenocarcinoma (LAC) or poorly differentiated squamous cell carcinoma (SCC). This study aimed to evaluate the diagnostic role of…
Read MoreEfficacy of postoperative immunotherapy on MPM patients after CRS + HIPEC: A single-center retrospective study based on propensity score matching
International Journal of Cancer 2025 September 2 [Link] Xin-Li Liang, Yan-Dong Su, Yu-Bin Fu, Yang Yu, Xin-Bao Li, Zhong-He Ji, Ru Ma, Rui Yang, He-Liang Wu, Yu-Run Cui, Yan Li Abstract To investigate the efficacy of postoperative immunotherapy in patients with malignant peritoneal mesothelioma (MPM) after cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC).…
Read More